Targeting tauopathy with engineered tau-degrading intrabodies

Authors

Gilbert Gallardo, Washington University School of Medicine in St. Louis
Connie H Wong, Washington University School of Medicine in St. Louis
Sara M Ricardez, Washington University School of Medicine in St. Louis
Carolyn N Mann, Washington University School of Medicine in St. Louis
Kent H Lin, Washington University School of Medicine in St. Louis
Cheryl E G Leyns, Washington University School of Medicine in St. Louis
Hong Jiang, Washington University School of Medicine in St. Louis
David M Holtzman, Washington University School of Medicine in St. Louis

Journal

Molecular Neurodegeneration

Publication Date

10-22-2019

Volume

14

Issue

1

First Page

38

Document Type

Open Access Publication

DOI

10.1186/s13024-019-0340-6

Rights and Permissions

Gallardo et al. Molecular Neurodegeneration (2019) 14:38 https://doi.org/10.1186/s13024-019-0340-6 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Recommended Citation

Gallardo, Gilbert; Wong, Connie H; Ricardez, Sara M; Mann, Carolyn N; Lin, Kent H; Leyns, Cheryl E G; Jiang, Hong; and Holtzman, David M, "Targeting tauopathy with engineered tau-degrading intrabodies." Molecular Neurodegeneration. 14, 1. 38 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8891